Posted by Michael Wonder on 16 May 2022
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS
16 May 2022 - Durvalumab recommended as an option for treating non-small-cell lung cancer.
More than 400 people in England with locally advanced unresectable non-small-cell lung cancer, whose tumours express PD-L1 on 1% or more of cells and whose disease has not progressed following concurrent platinum-based chemoradiation, could receive the immunotherapy treatment.
